Click Therapeutics announced today that it received FDA breakthrough device designation for its CT-132 prescription digital therapeutic (PDT). New York-based Click designed CT-132 as an adjunctive preventive treatment for episodic migraine in patients 18 years old and up. “We are thrilled to receive this Breakthrough designation as it will facilitate collaborative discussions with the FDA […]
clicktherapeutics
BD promotes Polen to COO | Personnel Moves – October 3, 2018
Becton Dickinson (NYSE:BDX) said today it named current president Tom Polen as its new chief operating officer, filling a role that has been empty since 2016. Polen was appointed president in April 2017, and will continue to report to chairman and CEO Vincent Forlenza, the Franklin Lakes, N.J.-based company said. In his new position, Polen will […]
Sanofi Ventures leads $17m round for Click Therapeutics
Click Therapeutics said today that it landed a $17 million round, led by Sanofi‘s (NYSE:SNY) venture arm, to fund its platform of prescription digital therapeutics. The company’s commercial product, Clickotine, is designed to help people quit smoking. The digital smoking cessation program uses a personalized plan to help people overcome tobacco cravings, adhere to medication regimens and […]
